Connect Biopharma: Phase 2b Data Shows Rapid and Sustained Improvement in Atopic Dermatitis
Global clinical-stage biopharmaceutical company, Connect Biopharma (Nasdaq: CNTB), has announced that post hocdata analysis from its Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD) showed a rapid and sustained improvement in AD signs and symptoms.
Connect’s share price climbed 19% following the news this week.
Highlights
- Researchers reported that CBP-201 demonstrated rapid improvement in AD as early as Week 2 and sustained at Week 16.
- Improvement was noted across four body regions, the head and neck, trunk, upper limbs and lower limbs, compared to placebo.
- The results were observed with dosing regimens of both 2- and 4-weeks.
- In addition to overall AD improvement across all four body regions, researchers also observed improvement for each classification of AD symptoms: erythema, induration/papulation, lichenification and excoriation, within each body region.
- AD signs and symptoms in the head and neck region are particularly difficult to control and greatly affect patient quality of life.
- The data were presented as an ePoster and online oral presentation this week at the American Academy of Dermatology Annual Meeting in New Orleans.
About Connect Biopharma
Connect Biopharma is a global, clinical-stage biopharmaceutical company developing innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The company is advancing CBP-307 for the treatment of ulcerative colitis, and CBP-174 for the treatment of pruritus associated with AD.
